Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection

Annals of Oncology

Volumn 23, Issue 2, 2012, Pages 421-426

  Mya, D H T ^a   Han, S T ^b   Linn, Y C ^a   Hwang, W Y K ^a   Goh, Y T ^a   Tan, D C L ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b CHRIST S COLLEGE   (United Kingdom)

Author keywords

Hepatitis B; Immunomodulatory; Lamivudine; Myeloma; Thalidomide

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; MELPHALAN; PREDNISOLONE; THALIDOMIDE; VINCRISTINE; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASIAN; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDEMIC DISEASE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; INCIDENCE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NONHUMAN; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SALVAGE THERAPY; SIDE EFFECT; VIRUS LOAD; VIRUS MUTANT; VIRUS REACTIVATION; VIRUS STRAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BORONIC ACIDS; COMORBIDITY; ENDEMIC DISEASES; FEMALE; HEPATITIS B; HUMANS; IMMUNOLOGIC FACTORS; INCIDENCE; LAMIVUDINE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PREVALENCE; PROSPECTIVE STUDIES; PYRAZINES; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; VIRUS ACTIVATION;

EID: 84856338990     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr142     Document Type: Article

References (36)

1. Nakamura Y, Motokura T, Fujita A et al. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-91. Cancer 1996; 78: 2210-2215.
2. Yeo W, Chan PKS, Zhong S et al. Frequency of hepatitis B virus reactivation in cancer patient undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307.
3. Kumagai K, Takagi T, Nakamura S et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997; 8: 107-109.
4. Liang R, Lau GKK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers. J Clin Oncol 1999; 17: 394-398.
5. Liang R, Lok ASF, Lai CL et al. Hepatitis B infection in patients with lymphomas. Hematol Oncol 1990; 8: 261-270.
6. Yeo W, Steinberg JL, Tam JS et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 1999; 59: 263-269.
7. Lim ST, Fei G, Quek R et al. The relationship of hepatitis B infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis. Eur J Haematol 2007; 79: 132-137.
8. Marcucci F, Mele A, Spada E et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 2006; 91: 554-557.
9. Wang F, Xu RH, Han B et al. High incidence of hepatitis B infection in B-cell subtype non-Hodgkin's lymphoma compared with other cancers. Cancer 2007; 109: 1360-1364.
10. Kuniyoshi M, Nakamuta M, Sakai H et al. Prevalence of hepatitis B or C virus in patients with non-Hodgkin's lymphoma. J Gastroenterol Hepatol 2001; 16: 215-219.
11. Park SC, Jeong SH, Kim J et al. High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin's lymphoma in Korea. J Med Virol 2008; 80: 960-966.
12. Yeo W, Tung CC, Nancy WY et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-611.
13. Clark FL, Drummond MW, Chambers S et al. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 385-387.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-484.
15. Peto R, Pike MC. Conservatism of the approximation sigma (O-E)2-E in the log rank test for survival data or tumor incidence data. Biometrics 1973; 29: 579-584.
16. James L, Fong CW, Foong BH et al. Hepatitis B Seroprevalence Study 1999. Singapore Med J 2001; 42: 420-424.
17. Chen MH, Hsiao LT, Chiou TJ et al. High prevalence of occult hepatitis B infection in patients with B-cell non-Hodgkin's lymphoma. Ann Hematol 2008; 87: 475-480.
18. Wands JR, Chura CM, Roll FJ et al. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975; 68: 105-112.
19. Lok ASF, Liang R, Chiu EKW et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastroenterology 1991; 100: 182-188.
20. Soh LT, Ang PT, Sng I et al. Fulminant hepatic failure in non-Hodgkin's lymphoma patients treated with chemotherapy. Eur J Cancer 1992; 28A: 1338-1339.
21. Li YH, He YF, Jiang WQ et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006; 106: 1320-1325.
22. Vassiliadis T, Garipidou V, Tziomalos K et al. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy-a prospective case series. Am J Hematol 2005; 80: 197-203.
23. Lau GK, Yiu HH, Fong DY et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-1749.
24. Nolte A, Buhmann R, Emmerich B et al. Reconstitution of the cellular immune response after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin's lymphoma. Br J Haematol 2000; 108: 415-423.
25. Ashihara E, Shimazaki C, Yamagata N et al. Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis. Bone Marrow Transplant 1994; 13: 377-381.
26. Scheid C, Pettengell R, Ghielmini M et al. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1995; 15: 901-906.
27. Talmadge JE, Reed EC, Kessinger A et al. Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant 1996; 17: 101-109.
28. Lucas KG, Small TN, Heller G et al. The development of cellular immunity to Epstein Barr virus after allogeneic bone marrow transplantation. Blood 1996; 87: 2594-2603.
29. Tilkin AF, Bagot M, Dreyfus F et al. Reconstitution of cytotoxic T lymphocyte activity following allogeneic bone marrow transplantation in man. Transplantation 1987; 44: 303-308.
30. Haslett PA, Corral LG, Albert M et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8 subset. J Exp Med 1998; 187: 1885-1892.
31. Haslett PA, Hanekom WA, Muller G, Kaplan G. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis 2003; 187: 946-955.
32. Gandhi AK, Kang J, Capone L et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010; 10: 155-167.
33. Hsu AK, Quach H, Tai T et al. The immuno-stimulatory effect of lenalidomide on NK cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011; 117: 1605-1613.
34. Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009; 94(7): 998-1005.
35. Asher CK, Pieter S, Michael WS et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008; 26: 4784-4790.
36. Blanco B, Perez-Simon JA, Sanchez-Abarca LI et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006; 107: 3575-3583.